Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.460, 2004-01, pp. : 10-10
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Cisplatin/etoposide/paclitaxel: Drug hypersensitivity: case report
Reactions Weekly, Vol. 1, Iss. 1254, 2009-01 ,pp. :
Access to resources
Recommend
Paclitaxel vs cyclophosphamide, + cisplatin, for ovarian cancer
Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. :
Carboplatin/cisplatin/paclitaxel: Various toxicities: case report
Reactions Weekly, Vol. 1, Iss. 1364, 2011-01 ,pp. :
Cisplatin/paclitaxel: Ischaemic colitis: case report
Reactions Weekly, Vol. 1, Iss. 1324, 2010-01 ,pp. :
Gemcitabine alone or in combination with cisplatin cost effective in NSCLC
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 363, 2002-01 ,pp. :